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A commercially available rapid fluorescent in situ hybridization (FISH) test, (seaFAST H. pylori Combi-Kit;
SeaPro Theranostics International, Lelystad, The Netherlands) was used to simultaneously detect the presence
of Helicobacter pylori and determine clarithromycin susceptibility in paraffin-embedded biopsy sections. The
FISH method was found to be 97% sensitive, 94% specific for the detection of H. pylori and comparable to agar
dilution for the detection of resistance to clarithromycin.
Helicobacter pylori is a pathogen of the gastric mucosa and a
major cause of peptic ulcer disease and chronic gastritis (6).
The usual treatment regimen for H. pylori infection consists of
two antimicrobials in combination with an agent to lower gastric acid with or without bismuth subsalicylate. Clarithromycin
used together with either amoxicillin or metronidazole is a
common combination. A high eradication rate occurs when the
isolate is susceptible to clarithromycin, but infection with clarithromycin-resistant organisms is often predictive of treatment failure (8, 10).
H. pylori resistance to clarithromycin has been increasing
worldwide (3, 8, 10). The method approved by the National
Committee for Clinical Laboratory Standards (NCCLS) to test
for antimicrobial susceptibility of H. pylori is agar dilution (9).
Due to the complexities of this methodology, it is usually performed only in specialized laboratories, making it generally
unavailable for routine clinical use. An alternative method
offered by some commercial laboratories is the Epsilometer (E
test) test method (AB Biodisk, Solna, Sweden); however, this
method has not been approved by the NCCLS for susceptibility
testing of H. pylori (1, 9). Both agar dilution and the E test
require culturing of the organism, which is by nature fastidious
and slow growing. Therefore, results are often not available for
2 weeks or more. Consequently, empirical therapy for H. pylori
infection is commonly employed. A more expeditious methodology for susceptibility testing of H. pylori could be an effective
tool to help guide therapy of H. pylori infections. The purpose
of this study was to evaluate a rapid fluorescent in situ hybridization (FISH) test that simultaneously detects H. pylori and
clarithromycin resistance in formalin-fixed, paraffin-embedded
biopsy sections.
Gastric biopsy specimens from both the antrum and the
fundus were collected on all patients enrolled in an ongoing
reinfection study at a tertiary care hospital in Anchorage,

Alaska (8). We randomly selected 35 isolates from 176 available biopsy specimens that tested H. pylori culture negative.
From 286 specimens that tested H. pylori culture positive, we
randomly selected 35 clarithromycin-sensitive H. pylori strains
and 33 clarithromycin-resistant H. pylori strains, as determined
by agar dilution, and tested them using FISH.
Cultures were performed by placing homogenized biopsy
tissue on two types of solid media: blood agar (tryptic soy agar
with 5% sheep blood) and brucella agar containing 10% horse
blood, trimethoprim, vancomycin, and polymyxin B (Remel,
Lenexa, Kans.). The inoculated media were incubated at 37°C,
12% CO2 and 98% humidity for up to 10 days. Isolates were
identified as H. pylori on the basis of positive catalase, oxidase,
and urease reactions, typical colony morphology, and curved
gram-negative bacilli on gram-stained smears.
The clarithromycin MIC was determined by the agar dilution method using the guidelines set by the NCCLS (9). The
recommended MIC levels of this method for determining antimicrobial susceptibility of H. pylori to clarithromycin are as
follows: sensitive, ⱕ0.25 g/ml; intermediate, 0.5 g/ml; resistant, ⱖ1.0 g/ml. We defined a MIC of ⬎0.25 g/ml as resistance to clarithromycin.
FISH was performed on deparaffinized tissue sections from
the randomly selected specimens, using the following fluorescence-labeled oligonucleotide probes: A2143G (ClaR1),
A2144G (ClaR2), and A2143C (ClaR3), targeting the most
prevalent point mutations for clarithromycin resistance, and
Hpy-1 for the specific identification of H. pylori (7, 13, 15). The
probes for resistance were labeled with the fluorochrome Cy3
(red signal), and the probe for H. pylori identification was
labeled with fluorescein (green signal). After hybridization was
complete, the specimens were analyzed with a fluorescent microscope equipped with filters for green and red fluorescence.
Of the 68 culture-positive specimens, 66 (97%) were positive
for H. pylori by FISH and 2 were negative. Of the 35 culturenegative biopsies, 33 (94.2%) were negative by FISH and 2
were positive. The sensitivity and specificity of FISH for the
detection of H. pylori in biopsy specimens was 97% (95%

* Corresponding author. Mailing address: Arctic Investigations Program, CDC, 4055 Tudor Centre Drive, Anchorage, AK 99508. Phone:
(907) 729-3445. Fax: (907) 729-3429. E-mail: jmorris@cdc.gov.
3494

Downloaded from http://jcm.asm.org/ on March 28, 2014 by Washington University in St. Louis

Julie M. Morris,1* Alisa L. Reasonover,1 Michael G. Bruce,1 Dana L. Bruden,1
Brian J. McMahon,1,2 Frank D. Sacco,2 Douglas E. Berg,3
and Alan J. Parkinson1

VOL. 43, 2005

NOTES

TABLE 1. Discrepant results testing for H. pylori and resistance to
clarithromycin between agar dilution and FISH among 103
specimens tested by both methods
Culture result
No. of
specimens

a
b

MIC

Positive
0.12
Positive
0.25
Positive
0.06
Positive
8.0
Positive
0.06
Positive ⱖ16.0
Negative NAb

FISH result

Clarithromycin
result

H. pylori
result

Clarithromycin
result

Susceptible
Susceptible
Susceptible
Resistant
Susceptible
Resistant
NA

Positive
Positive
Positive
Positive
Negative
Negative
Positive

Resistant
Resistant
Resistant
Susceptible
NA
NA
Resistant

Both clarithromycin-sensitive and resistant organisms seen with FISH.
NA, Not applicable.

confidence interval [CI], 91% to 99%) and 94% (95% CI, 81%
to 99%), respectively.
When tested by agar dilution, H. pylori clarithromycin MICs
were predominately either ⱕ0.25 g/ml (35 isolates) or ⱖ16
g/ml (31 isolates). Two isolates had a MIC of 8.0 g/ml, and
no isolates had intermediate MICs.
Of 33 specimens resistant to clarithromycin by agar dilution,
32 were H. pylori positive by FISH, and 31 of these were also
resistant to clarithromycin by FISH. Of 35 specimens sensitive
to clarithromycin by agar dilution, 34 were H. pylori positive by
FISH, and 30 of these were also sensitive to clarithromycin by
FISH, resulting in a sensitivity of 97% (95% CI, 84% to 100%)
and a specificity of 88% (95% CI, 73% to 96%) for the detection of clarithromycin resistance for FISH compared with agar
dilution.
Discrepant results between FISH and agar dilution were
found in nine biopsy specimens; four isolates determined to be
clarithromycin sensitive by agar dilution were found to be
clarithromycin resistant by FISH. Of these, two were found to
contain a mixed population of both sensitive and resistant H.
pylori organisms by the FISH method. One specimen yielded
an H. pylori isolate resistant by agar dilution (MIC, 8.0 g/ml)
but sensitive by FISH. Two specimens were found to be negative for H. pylori by the FISH method but by culture grew H.
pylori isolates that had MICs of 0.06 g/ml and ⬎16.0 g/ml by
agar dilution, and two specimens that were H. pylori negative
by culture were positive by the FISH method (Table 1).
Our study demonstrates that this rapid FISH test is a sensitive and specific method for the detection of H. pylori and is
comparable to agar dilution for the detection of clarithromycin-resistant organisms. Our results are consistent with those in
previous studies by Rüssmann et al., which found the same
method to be comparable to E test, disk diffusion, and culture
when using shock-frozen biopsies (13, 14), and the more recently published study by Jüttner et al., who found this FISH
method to be comparable to culture and E test when using
formalin-fixed, paraffin-embedded biopsy specimens (4).
The advantages of the FISH method are the rapid detection
of H. pylori and its susceptibility to clarithromycin using paraffin-embedded biopsy sections and fluorescence microscopy.
For example, once tissue sections are deparaffinized in the
laboratory, results from FISH testing can be available in 3 h. In
addition, the FISH method is able to detect mixed populations

of clarithromycin-sensitive and resistant organisms and may
explain some of the treatment failures that occur in persons
infected with clarithromycin-sensitive isolates as determined
by culture and agar dilution. For instance, in a separate study
(J. M. Morris, D. L. Bruden, and A. J. Parkinson, unpublished
data), we identified 11 biopsy specimens containing isolates
sensitive to clarithromycin by agar dilution from seven patients
who failed clarithromycin therapy in spite of a 100% reported
medication compliance; three specimens from two patients
demonstrated the presence of a mixed population of clarithromycin-sensitive and resistant H. pylori by FISH. These discrepancies and those in our current study are most likely due to
inadequate biopsy sampling coupled with the patchy growth
distribution of the organism in the stomach (5, 7, 11). It is also
possible that low numbers of clarithromycin-resistant organisms present within a large population of clarithromycin-susceptible organisms become suppressed and are not expressed
by phenotypic methods, such as culture and agar dilution (3).
Since the FISH method is not dependent on the viability of
microorganisms, it is likely that it would detect H. pylori in
biopsies that fail to yield H. pylori by culture. Also, FISH may
be more successful than histology in detecting low numbers of
H. pylori in gastric tissue, as may occur after recent antibiotic
treatment.
One of the limitations of FISH is its inability to determine
the susceptibility of H. pylori to antibiotics other than clarithromycin. For example, it has been found that tetracycline resistance is due to specific mutations in both copies of the 16S
rRNA of H. pylori (2, 12). These changes are analogous to the
specific point mutations found at the 23S rRNA when H. pylori
is resistant to clarithromycin. Therefore, it is likely FISH could
be adapted to determine tetracycline susceptibility; however, at
present, resistance to tetracycline is rare (2).
In conclusion, we suggest that an additional slide could be
prepared for FISH testing from formalin-fixed, paraffin-embedded biopsy sections at the same time a histology slide is
prepared, in order to determine antimicrobial susceptibility to
clarithromycin in instances where the provider is interested in
treatment with a clarithromycin-based regimen. This could potentially result in a more judicious use of clarithromycin and a
higher eradication rate than that with empirical therapy.
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